This list is an analysis based on recent market events. It's not an investment recommendation.
About
INOVIQ Ltd specializes in the research, development, and commercialization of diagnostic and exosome-based products, aiming to improve the detection and treatment of cancer and other conditions across Australia and the United States. Its current portfolio includes the hTERT test, an immunocytochemistry assay that serves as a supplementary tool for urine cytology in bladder cancer screening, alongside EXO-NET, designed for the capture and isolation of exosomes from liquid biopsy specimens. The company also boasts a robust diagnostic pipeline, featuring blood tests currently under development for various cancers, including ovarian and breast cancer. Originally incorporated in 1983 and formerly known as BARD1 Life Sciences Limited until its rebranding to INOVIQ Ltd in December 2021, the company maintains its headquarters in Notting Hill, Australia.
The current price of EGQ0.STU is €0.09 EUR — it has decreased by -13.27% in the past 24 hours. Watch Inoviq stock price performance more closely on the chart.
What is Inoviq stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Inoviq stocks are traded under the ticker EGQ0.STU.
Is Inoviq stock price growing?▼
EGQ0.STU stock has fallen by -2.3% compared to the previous week, the month change is a -19.05% fall, over the last year Inoviq has showed a -59.91% decrease.
What is Inoviq market cap?▼
Today Inoviq has the market capitalization of 11.97M
When is the next Inoviq earnings date?▼
Inoviq is going to release the next earnings report on February 19, 2027.
What is Inoviq revenue for the last year?▼
Inoviq revenue for the last year amounts to 313,410.35 EUR.
What is Inoviq net income for the last year?▼
EGQ0.STU net income for the last year is -4.01M EUR.
How many employees does Inoviq have?▼
As of September 09, 2026, the company has 15 employees.